Form 4: Y-mAbs Therapeutics SVP Torben Lund-Hansen Executes Stock Option and Sells Shares

Torben Lund-Hansen, SVP & Chief Technical Officer of Y-mAbs Therapeutics, exercised stock options and sold 50,000 shares of common stock on August 28, 2024.

Summary

• On August 28, 2024, Torben Lund-Hansen, SVP & Chief Technical Officer of Y-mAbs Therapeutics, exercised an employee stock option to acquire 50,000 shares of common stock at a price of $4.38 per share.
• Simultaneously, Lund-Hansen sold 50,000 shares of common stock at a weighted average price of $15.37, with individual sales ranging from $15.00 to $15.6978.
• Following these transactions, Lund-Hansen directly owns 35,600 shares and indirectly owns 45,662 shares through Toluha ApS.
• He also retains 100,000 employee stock options.

Sentiment

Score: 5

Explanation: This is a neutral report of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing reflects insider trading activity, which is a common occurrence in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The exercise and sale of shares are typical activities for executives holding stock options.
• The reported price range of $15.00 to $15.6978 is within a normal range for stock trading activity.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but it is a common practice.
• The exercise of stock options dilutes existing shareholders' equity to a small degree.

Key Dates